Natixis Advisors LLC Has $20.46 Million Holdings in GSK plc (NYSE:GSK)

Natixis Advisors LLC increased its position in shares of GSK plc (NYSE:GSK - Free Report) by 20.0% during the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 500,495 shares of the pharmaceutical company's stock after acquiring an additional 83,433 shares during the quarter. Natixis Advisors LLC's holdings in GSK were worth $20,460,000 at the end of the most recent quarter.

Several other hedge funds have also recently added to or reduced their stakes in the stock. 1832 Asset Management L.P. boosted its stake in shares of GSK by 9.1% during the 1st quarter. 1832 Asset Management L.P. now owns 3,078 shares of the pharmaceutical company's stock worth $132,000 after acquiring an additional 257 shares during the period. Boltwood Capital Management boosted its position in shares of GSK by 2.5% during the 2nd quarter. Boltwood Capital Management now owns 11,133 shares of the pharmaceutical company's stock valued at $429,000 after purchasing an additional 270 shares in the last quarter. First Affirmative Financial Network boosted its holdings in GSK by 4.7% in the second quarter. First Affirmative Financial Network now owns 6,359 shares of the pharmaceutical company's stock worth $245,000 after acquiring an additional 283 shares in the last quarter. EverSource Wealth Advisors LLC increased its position in GSK by 9.4% in the second quarter. EverSource Wealth Advisors LLC now owns 3,542 shares of the pharmaceutical company's stock worth $137,000 after buying an additional 303 shares during the last quarter. Finally, Mesirow Financial Investment Management Inc. grew its position in shares of GSK by 2.0% in the third quarter. Mesirow Financial Investment Management Inc. now owns 16,693 shares of the pharmaceutical company's stock valued at $682,000 after purchasing an additional 323 shares in the last quarter. Institutional investors and hedge funds own 15.74% of the company's stock.

Insider Transactions at GSK

In other GSK news, major shareholder Plc Gsk purchased 2,791,930 shares of the firm's stock in a transaction on Friday, September 27th. The shares were purchased at an average price of $8.00 per share, for a total transaction of $22,335,440.00. Following the completion of the purchase, the insider now directly owns 16,775,691 shares of the company's stock, valued at approximately $134,205,528. This represents a 19.97 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 10.00% of the stock is owned by insiders.

GSK Stock Performance

Shares of NYSE:GSK traded down $0.14 on Tuesday, reaching $33.55. 6,742,206 shares of the company's stock were exchanged, compared to its average volume of 4,120,409. The firm has a market capitalization of $69.53 billion, a price-to-earnings ratio of 21.88, a PEG ratio of 1.28 and a beta of 0.66. GSK plc has a fifty-two week low of $32.83 and a fifty-two week high of $45.92. The business's 50-day moving average is $38.88 and its two-hundred day moving average is $40.61. The company has a quick ratio of 0.53, a current ratio of 0.81 and a debt-to-equity ratio of 0.98.

GSK Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, January 9th. Shareholders of record on Friday, November 15th will be issued a $0.3928 dividend. This represents a $1.57 annualized dividend and a dividend yield of 4.68%. This is a boost from GSK's previous quarterly dividend of $0.38. The ex-dividend date is Friday, November 15th. GSK's dividend payout ratio (DPR) is presently 99.35%.

Analyst Ratings Changes

A number of research analysts have weighed in on the company. Deutsche Bank Aktiengesellschaft downgraded GSK from a "buy" rating to a "hold" rating in a report on Friday. Argus raised shares of GSK to a "strong-buy" rating in a research note on Wednesday, August 7th. Guggenheim lowered shares of GSK from a "buy" rating to a "neutral" rating in a report on Thursday, October 31st. Jefferies Financial Group lowered shares of GSK from a "buy" rating to a "hold" rating and cut their price target for the stock from $53.00 to $39.50 in a research note on Tuesday, November 12th. Finally, Barclays raised shares of GSK to a "hold" rating in a report on Tuesday, August 27th. Seven equities research analysts have rated the stock with a hold rating and three have assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $43.25.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.